5o8f: Difference between revisions

No edit summary
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:


==Structure of a chimaeric beta3-alpha5 GABAA receptor in complex with nanobody Nb25 and pregnanolone==
==Structure of a chimaeric beta3-alpha5 GABAA receptor in complex with nanobody Nb25 and pregnanolone==
<StructureSection load='5o8f' size='340' side='right' caption='[[5o8f]], [[Resolution|resolution]] 3.20&Aring;' scene=''>
<StructureSection load='5o8f' size='340' side='right'caption='[[5o8f]], [[Resolution|resolution]] 3.20&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[5o8f]] is a 10 chain structure with sequence from [http://en.wikipedia.org/wiki/Camelus_glama Camelus glama] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O8F OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5O8F FirstGlance]. <br>
<table><tr><td colspan='2'>[[5o8f]] is a 10 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Lama_glama Lama glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O8F OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5O8F FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=P9N:Pregnanolone'>P9N</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.2&#8491;</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">GABRA5 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=P9N:1-[(3~{R},5~{R},8~{R},9~{S},10~{S},13~{S},14~{S},17~{S})-10,13-dimethyl-3-oxidanyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1~{H}-cyclopenta[a]phenanthren-17-yl]ethanone'>P9N</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5o8f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o8f OCA], [http://pdbe.org/5o8f PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5o8f RCSB], [http://www.ebi.ac.uk/pdbsum/5o8f PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5o8f ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5o8f FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o8f OCA], [https://pdbe.org/5o8f PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5o8f RCSB], [https://www.ebi.ac.uk/pdbsum/5o8f PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5o8f ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
[[http://www.uniprot.org/uniprot/GBRB3_HUMAN GBRB3_HUMAN]] Autism;Childhood absence epilepsy. Disease susceptibility is associated with variations affecting the gene represented in this entry.  
[https://www.uniprot.org/uniprot/GBRB3_HUMAN GBRB3_HUMAN] Autism;Childhood absence epilepsy. Disease susceptibility is associated with variations affecting the gene represented in this entry.
== Function ==
== Function ==
[[http://www.uniprot.org/uniprot/GBRB3_HUMAN GBRB3_HUMAN]] GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.  
[https://www.uniprot.org/uniprot/GBRB3_HUMAN GBRB3_HUMAN] GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.[https://www.uniprot.org/uniprot/GBRA5_HUMAN GBRA5_HUMAN] GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 21: Line 21:
</div>
</div>
<div class="pdbe-citations 5o8f" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 5o8f" style="background-color:#fffaf0;"></div>
==See Also==
*[[GABA receptor|GABA receptor]]
*[[GABAA receptor|GABAA receptor]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Camelus glama]]
[[Category: Homo sapiens]]
[[Category: Human]]
[[Category: Lama glama]]
[[Category: Aricescu, A R]]
[[Category: Large Structures]]
[[Category: Colibus, L De]]
[[Category: Aricescu AR]]
[[Category: Masiulis, S]]
[[Category: De Colibus L]]
[[Category: Miller, P S]]
[[Category: Masiulis S]]
[[Category: Pardon, E]]
[[Category: Miller PS]]
[[Category: Scott, S]]
[[Category: Pardon E]]
[[Category: Steyaert, J]]
[[Category: Scott S]]
[[Category: Gabaa receptor]]
[[Category: Steyaert J]]
[[Category: Ion channel]]
[[Category: Membrane protein]]
[[Category: Nanobody complex]]
[[Category: Neurosteroid]]
[[Category: Pregnanolone]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA